Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin

BACKGROUND Since the discovery of the vancomycin-resistant Staphylococcus aureus (VRSA) strain Mu50 (minimum inhibitory concentration [MIC] 8 mg/L), there has been concern about the potential spread of such strains throughout Japanese hospitals. Two important questions need to be answered: (1) what is the prevalence of VRSA, and (2) by what mechanism does vancomycin resistance occur. METHODS The vancomycin susceptibilities of three methicillin-resistant S aureus (MRSA) strains (Mu50, Mu3, and H1) and the methicillin-susceptible S aureus type strain FDA209P were compared by MIC determinations and population analysis. Mu3 (MIC 3 mg/L) was isolated from the sputum of a patient with pneumonia after surgery who had failed vancomycin therapy. H1 (MIC 2 mg/L), which is a representative vancomycin-susceptible MRSA strain, was isolated from a patient with pneumonia who responded favourably to vancomycin therapy. Subclones of Mu3 with increased resistance against vancomycin were selected with serial concentrations of vancomycin and their MICs were determined. The prevalence of VRSA and Mu3-like strains in Japanese hospitals was estimated by population analysis from 1149 clinical MRSA isolates obtained from 203 hospitals throughout Japan. The genetic traits of the Mu3 and Mu50 strains were compared with clonotypes of MRSA from around the world. FINDINGS Mu3 and Mu50 had an identical pulsed-field gel electrophoresis banding pattern. When grown in a drug-free medium, Mu3 produced subpopulation of cells with varying degrees of vancomycin resistance, thus demonstrating natural heterogeneity, or variability, in susceptibility to vancomycin. In the presence of vancomycin, Mu3 produced subclones with resistance roughly proportional to the concentrations of vancomycin used. Selection of Mu3 with 8 mg/L or more of vancomycin gave rise to subclones with vancomycin resistance equal to that of Mu50 (MIC 8 mg/L) at a frequency of 1/1,000,000. During screening of Japanese MRSA strains, no strain of VRSA additional to Mu50 was found. The prevalence of MRSA isolates heterogeneously resistant to vancomycin was 20% in Juntendo University Hospital, 9.3% in the other seven university hospitals, and 1.3% in non-university hospitals or clinics. INTERPRETATION Heterogeneously resistant VRSA is a preliminary stage that allows development into VRSA upon exposure to vancomycin. Heterogeneously resistant VRSA was found in hospitals throughout Japan. This finding could explain, at least partly, the frequent therapeutic failure of MRSA infection with vancomycin in Japan.

[1]  A. Tomasz,et al.  Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus , 1997, Journal of bacteriology.

[2]  M. Barber Naturally Occurring Methicillin-Resistant Staphylococci , 1964 .

[3]  C. Sanders,et al.  Vancomycin concentration in human tissues--preliminary report. , 1979, The Journal of antimicrobial chemotherapy.

[4]  S. Gupta,et al.  Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. , 1992, The Journal of infectious diseases.

[5]  D. Shlaes,et al.  Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Inoue,et al.  [A survey of Staphylococcus aureus for typing and drug-resistance in various areas of Japan during 1992 and 1993]. , 1994, The Japanese journal of antibiotics.

[7]  A. Iwamoto,et al.  A retrospective study of methicillin-resistantStaphylococcus aureus clinical strains in Tokyo university hospital , 1995 .

[8]  G. Kaatz,et al.  Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. , 1990, The Journal of infectious diseases.

[9]  K. Hiramatsu Molecular Evolution of MRSA , 1995, Microbiology and immunology.

[10]  Teruyo Ito,et al.  Genetic basis for molecular epidemiology of MRSA , 1997, Nihon saikingaku zasshi. Japanese journal of bacteriology.

[11]  P. Courvalin Resistance of enterococci to glycopeptides , 1990, Antimicrobial Agents and Chemotherapy.

[12]  K. Hiramatsu,et al.  Evolution and resistance expression of MRSA. Evaluation of beta-lactam antibiotics against a set of isogenic strains with different types of phenotypic expression. , 1995, Acta biochimica Polonica.

[13]  R. Goering,et al.  Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. , 1995, The Journal of infectious diseases.

[14]  L. Peterson,et al.  Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance , 1992, Clinical Microbiology Reviews.

[15]  F. Tenover,et al.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. , 1997, The Journal of antimicrobial chemotherapy.

[16]  K. Dyke Penicillinase production and intrinsic resistance to penicillins in methicillin-resistant cultures of Staphylococcus aureus. , 1969, Journal of medical microbiology.

[17]  K. Hiramatsu,et al.  Molecular cloning and mapping of 16S-23S rRNA gene complexes of Staphylococcus aureus , 1993, Journal of bacteriology.